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Edited by Vladimir SkulachevAbstract The aim of the present study was to investigate a pos-
sible role of the AP-1 signaling cascade in the process of wasting
associated with cancer cachexia at the level of skeletal muscle.
The injection of virus containing the TAM67 protein (a blocker
of the AP-1 protein) to the gastrocnemius muscle of tumour-
bearing rats resulted in a signiﬁcant recovery of the muscle mass
(which is dramatically reduced as a result of tumour burden),
therefore suggesting that AP-1 is certainly involved in the signal-
ing associated with muscle protein accretion. In conclusion, the
gene therapy approach presented here clearly suggests an impor-
tant role for AP-1 in muscle signaling during catabolic states.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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One of the most common manifestations of advanced malig-
nant disease is the development of cancer cachexia. Cachexia
occurs in the majority of cancer patients before death and it
is responsible for the death of 22% of cancer patients [1].
The abnormalities associated with cancer cachexia include an-
orexia, weight loss, muscle loss and atrophy, anemia and met-
abolic alterations [2–4]. The degree of cachexia is inversely
correlated with the survival time of the patient and it always
implies a poor prognosis [5,6]. Perhaps one of the most rele-
vant characteristics of cachexia is that of asthenia (or lack of
muscular strength), which reﬂects the important muscle waste
that takes place in the cachectic cancer patient [3]. Asthenia is
also characterized by a general weakness as well as physical
and mental fatigue [7]. In addition, lean body mass depletion
is one of the main trends of cachexia and it involves not only
skeletal muscle but also cardiac proteins, resulting in impor-
tant alterations in heart performance.
Several cytokines have been shown to mimic many of the
metabolic abnormalities found in the cancer patient duringAbbreviations: NF-jB, nuclear factor kappa B; AP-1, activator protein
1; MHC, sarcomeric myosin heavy chain; TNF-a, tumour necrosis
factor-alpha; PIF, proteolysis-inducing factor; COPD, chronic obstr-
uctive respiratory syndrome; GFP, green ﬂuorescent protein
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cerning muscle wasting, the role of tumour necrosis factor-al-
pha (TNF-a) seems very clear. Thus, administration of TNF-a
to rats results in an increased skeletal muscle proteolysis asso-
ciated with an increase in both gene expression and higher lev-
els of free and conjugated ubiquitin [9–12]. In addition, the
in vivo action of TNF-a during cancer cachexia does not seem
to be mediated by interleukin-1 (IL-1) [13] or glucocorticoids
[14]. Concerning a possible direct action of TNF-a on muscle
proteolysis, the presence of both p55 and p75 TNF-a receptors
has been described [15–17], and we have demonstrated that the
action of the cytokine on the induction of ubiquitin-dependent
proteolysis can be direct [12]. Other studies have shown that
the ubiquitin-dependent proteolytic system is activated in skel-
etal muscle in both humans [18] and many experimental mod-
els [16,19–21]. Other cytokines, such as IL-1 or interferon-c are
also able to activate ubiquitin gene expression. Therefore,
TNF-a alone or in combination with other cytokines, seems
to mediate most of the changes concerning nitrogen metabo-
lism associated with cachectic states. In addition to the massive
muscle protein loss, during cancer cachexia muscle DNA is
also decreased, similarly to what is observed in skeletal muscle
of chronic heart failure patients suﬀering from cardiac cachex-
ia [22], this leading to apoptosis measured as DNA fragmenta-
tion [23]. Interestingly, TNF-a can mimic the apoptotic
response in muscle of healthy animals [24].
In order to deﬁne successful approximations for the pharma-
cological treatment of cachexia, a better knowledge of the dif-
ferent intracellular signaling pathways linked to the muscle
wasting process is essential. This is especially important since
there is a plethora of mediators that have been proposed as
being responsible for the muscle protein abnormalities found
in cachexia. From this point of view it is interesting to remark
that previous studies have shown an involvement of both nu-
clear factor kappa B (NF-jB) and activator protein 1 (AP-1)
signaling cascades during sepsis [25]. Interestingly, in chronic
obstructive respiratory syndrome (COPD) patients (with evi-
dent muscle wasting) NF-jB has also been proposed as being
involved in the loss of skeletal muscle [26]. Studies from our
laboratory have shown that NF-jB does not seem to have a
key role in experimental cancer cachexia [27], while AP-1
seems to be involved [28]. Bearing all this in mind, the main
objective of the present work was to see if the administrations
of an adenoviral load genetically-engineered to express the
TAM67 protein (a negative dominant of c-jun/AP-1) was ableblished by Elsevier B.V. All rights reserved.
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rats. Additionally, a second objective of the present investiga-
tion was to investigate if the AP-1 signaling cascade was also
involved in the intracellular actions of TNF-a in the skeletal
muscle cells.2. Materials and methods
2.1. Animals
Male Wistar rats (Interfauna, Barcelona, Spain), of three days of age
were used. The animals were maintained at 22 ± 2 C with a regular
light–dark cycle (light on from 08:00 a.m. to 08:00 p.m.) and had free
access to food and water. All animal manipulations were made in
accordance with the European Community guidelines for the use of
laboratory animals.
2.2. Recombinant adenovirus preparation and administration to animals
Recombinant adenoviruses containing the cDNA encoding TAM67
dominant negative (AdCMV-TAM67) or the green ﬂuorescent protein
(AdCMV-GFP) [29] were used. A 1.3 kb-DNA fragment containing
the TAM67 dominant negative cDNA of human c-Jun gene was ex-
cised with EcoRI from the pSG5-TAM67 vector (kindly provided by
Dr. M.J. Birrer, Department of Cell and Cancer Biology, National
Cancer Institute, Rockville, MD 20850 [30]) and subcloned into pAC-
CMVpLpA downstream of CMV promoter. Plasmid pAdCMV-
TAM67 was used to isolate the corresponding AdCMV-TAM67 virus.
Viruses were ampliﬁed in 293 cells and concentrated to 1010–1011 pla-
que-forming units (pfu)/ml by centrifugation through a CsCl gradient
as described previously [29]. Viruses were aliquoted and stored at
80 C in phosphate-buﬀered saline (PBS). Viruses were titrated
by a serial dilution plaque-assay in noble agar overlaid 293 cells.
Approximately 5 · 108 pfu of AdCMV-TAM67 or AdCMV-GFP were
delivered to newborn (3–4 days) Wistar rats by intramuscular injection
in the right or left hind leg gastrocnemius muscle, and the right hind leg
was injected the same volume of PBS. Animals treated with AdCMV-
TAM67 or AdCMV-GFP were analyzed for transgene expression in
muscle. Only animals with detectable transgene expression were used
for further analysis.
2.3. Tumour inoculation
Rats were divided into two groups, namely controls and tumour
hosts. The latter received an intraperitoneal inoculum of 4 · 107 AH-
130 Yoshida ascites hepatoma cells obtained from exponential tu-
mours [31]. On day 4 after tumour transplantation, the animals were
weighed and anaesthetized with an i.p. injection of ketamine/xylazine
mixture (3:1) (Imalgene and Rompun, respectively). Tissues were
rapidly excised, weighed, and frozen in liquid nitrogen.2.4. Cell culture and transduction with adenovirus
The murine myoblasts C2C12 [32] were cultured in Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum, 20 mM glutamine, 100 U/ml penicillin, and 100 mg/ml strepto-
mycin (growth medium, GM). To induce diﬀerentiation cells at 80–
90% conﬂuence were shifted to DMEM supplemented with 2% fetal
bovine serum (diﬀerentiation medium, DM). For transduction experi-
ments, C2C12 cells were plated in GM for 24 h at a density of
1 · 105 cells/35-mm plate. Cells were then infected with the adenovi-
ruses [29]. After transduction, cells were transferred in DM and ex-
posed to TNF-a. Construction and use of recombinant adenoviruses
containing the TAM67 dominant negative (AdCMV-TAM67) or the
cDNA encoding a GFP (AdCMV-GFP). Gene delivery to muscle cul-
tures was achieved by exposing myoblasts, to the virus for 2 h at a mul-
tiplicity of infection of 100 [33].
2.5. Western blotting
For Western blots, protein extracts from tissues were prepared in
standard lysis buﬀer (50 mM Tris, pH 7.4, 0.25 mM sucrose and
5 mM EDTA, pH 8.0, and a cocktail of protease inhibitors) and
analyzed using anti-MyoD (Santa Cruz Sc-760), anti-MHC (Hybrid-
oma Bank MF20), anti-ciclin D1 (Santa Cruz Sc-8396), anti-c-Jun(Oncogene PC06), anti-a-tubulin (Sigma T5168), or anti-GFP (Clon-
thech CT6833) antibodies. 10 lg of total protein extract were loaded
for each sample. Speciﬁc proteins were detected with horseradish
peroxidase (HRP)-conjugated secondary antibodies and a chemilu-
minescence kit. The sizes of proteins were estimated by using protein
molecular-mass standards. Protein bands were quantiﬁed by scan-
ning densitometry (Phoretix 1D International Ltd., England).
2.6. In vivo detection of GFP expression
A Leica ﬂuorescence stereomicroscope (model LZ12) equipped with
a 50-W mercury lamp was used for high-magniﬁcation imaging. Selec-
tive excitation of GFP was produced through a D425/60 band-pass ﬁl-
ter and 470 DCXR dichroic mirror. Emitted ﬂuorescence was collected
through a long-pass ﬁlter GG475 (Chroma Technology, Brattleboro,
VT). At diﬀerent times after gene transfer, animals were anaesthetized
and photographed of region of interest were taken either directly
through the skin or after skin removal [34,35].
2.7. Biochemicals
These were all reagent grade and obtained either from Roche S.A.
(Barcelona, Spain) or from Sigma Chemical Co. (St. Louis, MO,
USA).
2.8. Statistical analysis
Statistical analysis of the data was performed by means of the Stu-
dent’s t test.3. Results and discussion
Cancer cachexia is a complex syndrome characterized by
weight loss, anorexia and profound disturbances in metabo-
lism which inﬂict serious muscle wasting. Several experimental
models have been used to study muscle wasting during cancer.
The rat ascites hepatoma Yoshida AH-130 is a suitable model
system to study the mechanisms involved in the establishment
of cachexia, because its growth causes rapid and progressive
loss of body weight and tissue waste in the host, particularly
in skeletal muscle [31].
Unfortunately, there seems to be a plethora of mediators in-
volved in the activation of muscle protein degradation during
cancer cachexia. Thus, several tumour compounds have been
proposed as activators of protein breakdown. Proteolysis-
inducing factor (PIF) has been involved in the activation of
muscle wasting in an experimental mouse model of cancer ca-
chexia [36]. Additionally, cytokines, TNF-a and IL-6 in partic-
ular, have also been reported as having a role in wasting in
skeletal muscle during cancer [37–40]. Changes in hormone
concentrations and/or sensitivity (insulin, glucocorticoids)
may also be involved in wasting [41–43]. Taking all of this into
consideration, the design of an eﬀective therapeutic strategy is
rather complicated due to the number of diﬀerent mediators.
Bearing this in mind, it may be more eﬀective to see if the ther-
apeutic strategy may be directed to an intracellular common
target, since some of the compounds mentioned seem to share
similar intracellular signaling pathways. However, few studies
have considered the intracellular signaling pathways associated
with muscle wasting. Penner et al. [25] reported that during
experimentally-induced sepsis there was an activation of both
NF-jB and AP-1 signaling pathways. In humans the muscle
wasting associated with the COPD seems to be also related
with activation of NF-jB associated with degradation of IjB
alpha [26].
Although some studies seem to indicate a role for NF-jB
in muscle wasting [44], previous results from our laboratory
Fig. 2. Gastrocnemius muscle weight (A) and MyoD content (B) in
control and tumour-bearing rats treated with AdCMV-TAM67. For
full details, see Section 2. The results are means ± S.E.M. of a
minimum of 4 animals for group. (1) Non-infected (N.I.). (2) AdCMV-
TAM67 (TAM67). (3) AdCMV-GFP (GFP). Statistical analysis of the
results (Student’s t test): control vs. tumour **,P 6 0.01; AdCMV-
TAM67 (TAM67) vs. AdCMV-GFP (GFP) , P 6 0.05.
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tion of AP-1 while NF-jB does not seem to be involved
[27,28]. We therefore decided to investigate if blockage of the
AP-1 signaling cascade could be an eﬀective therapeutic ap-
proach for the treatment of cancer cachexia.
Fig. 1A shows that the infection with the adenovirus was
highly eﬀective. Indeed, the photographs show that both in
gastrocnemius and soleus, the presence of the GFP was clearly
manifested 30 days following injection of the virus. It has to be
pointed out that, although the viral injection was performed at
the gastrocnemius muscle, there seems to be some spreading of
the viral load to adjacent muscles, such as soleus. Fig. 1B
shows a Western blot indicating that the proteins (TAM67
and GFP) were expressed only in the gastrocnemius muscles
where they were injected, right and left for AdCMV-TAM67
and AdCMV-GFP, respectively.
As shown in Fig. 2A, the implantation of the tumour re-
sulted in a signiﬁcant decrease in gastrocnemius mass (12%).
This result is in agreement with previous results from our re-
search group using the same experimental model [13,14,45].
Interestingly, the administration of the TAM67-containing
adenovirus resulted only in a 5% decrease in gastrocnemius
mass, this being statistically diﬀerent from the decrease ob-
served in the control animals injected with AdCMV-GFP,
where the decrease in muscle mass was around 10%. It can
therefore be speculated that the in vivo blockage of the AP-
1/c-jun signaling cascade is able to partially block muscle mass
loss. It has to be pointed out that, since the blockage of the
AP-1 transcription factor results only in a partial reversal of
the muscle mass, other transcription factors – such as NF-jB
– are likely to also be involved [44,46,47]. We then decide to
investigate if the eﬀects of AdCMV-TAM67 on muscle mass
were correlated with changes in the transcription factor
MyoD. As can be seen in Fig. 2B, the implantation of the tu-
mour resulted in a signiﬁcant decrease of MyoD content
(22%). Very interestingly, the injection of the AdCMV-Fig. 1. Analysis of eﬃciency of the in vivo adenoviral transduction
using ﬂuorescence microscopy and Western blotting. (A) Fluorescence
microscopy images of skeletal muscle from rats 30 days after injection
of the virus. (B) Western blot of gastrocnemius muscles injected with
AdCMV-TAM67 (TAM67) (injected in right thigh muscle) or
AdCMV-GFP (GFP) (injected in left thigh muscle). L: left muscle,
R: right muscle.TAM67 carrying virus neutralized the decrease in MyoD con-
tent and the presence of the tumour did not seem to signiﬁ-
cantly aﬀect the content of the transcription factor in the
tumour-bearing animals.
In previous studies involving experimental models of cancer
cachexia, we have described that cytokines, TNF-a in particu-
lar, may be the mediator(s) triggering muscle protein break-
down during catabolic states. In fact, both in vivo [9] and
in vitro [48], it has been described that this cytokine is respon-
sible for activating myoﬁbrillar protein degradation [49,50].
Bearing all this in mind, we decided to investigate whether
AP-1 was involved in the TNF-a signaling cascade in skeletal
muscle cell cultures. We therefore exposed C2C12 cells – both
control and adenovirus-infected – in culture to the action of
the cytokine. As can be seen in Fig. 3, the viral infection of
the muscle cell cultures was successful, the photograph show-
ing the GFP protein ﬂuorescence (Fig. 3A). Fig. 3B depicts a
Western blot of the TAM67, thus conﬁrming that the protein
was present in the transfected cells.
The data presented in Fig. 4 clearly show that the addition of
the TNF-a to the cell cultures resulted in a signiﬁcant decrease
both in the amount of MyoD (50%) (Fig. 4A) and sarcomeric
myosin heavy chain (MHC) (80%) (Fig. 4B). These results
agree with previous work from our laboratory using the same
cell culture system [48]. Very interestingly, the TAM67 express-
ing cells showed a resistance to the cytokine eﬀects on both
MyoD and MHC content. Several conclusions can be drawn
Fig. 3. Analysis of the in vitro adenoviral transduction using
ﬂuorescence microscopy and Western blotting. (A) Fluorescence
microscopy image of C2C12 diﬀerentiating myoblasts 72 h after
infection with AdCMV-GFP. (B) Western blot of C2C12 diﬀerentiat-
ing myoblasts 72 h after infection with AdCMV-TAM67.
Fig. 4. MyoD and MHC content in control and tumour-bearing rats
treated with AdCMV-TAM67. (A) MyoD content (B) MHC content.
For full details, see Section 2. The results are means ± S.E.M. of a
minimum of 4 animals for group. Non-infected (N.I.), AdCMV-
TAM67 (TAM67), AdCMV-GFP (GFP). Statistical analysis of the
results (Student’s t test): control vs. TNF-a \, P 6 0.05; \\, P 6 0.01;
AdCMV-GFP vs. AdCMV-TAM67 , P 6 0.05.
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cell culture system, clearly decreasing the myoﬁbrillar protein
content; (2) a good correlation of changes exist between the
transcription factor (MyoD) and the myoﬁbrillar protein con-
tent (MHC), since very similar changes aﬀect both of the pro-
teins; (3) the eﬀects of the cytokine on the protein content
involve the AP-1 signaling cascade; (4) the AP-1 transcription
may be involved in muscle cell diﬀerentiation since the simple
expression of the TAM67 protein (AP-1 blockade) increases
the amount of MHC (a protein clearly associated with skeletal
muscle diﬀerentiation) by 300% (Fig. 4B).
In fact, in order to conﬁrm this point from a diﬀerent angle,
we decided to measure the content of cyclin D1 (a protein
clearly associated with proliferation). As can be seen in
Fig. 5, the addition of TNF-a to the cell cultures resulted in
a signiﬁcant increase both in control (non-transduced) and
control (AdCMV-GFP-transduced) (30% and 70%, respec-
tively) in cyclin D1 content (in control both infected and
non-infected), suggesting that the action of the cytokine pro-
motes proliferation as opposed to diﬀerentiation. Very inter-
estingly, the presence of the TAM67 protein completely
abolished the eﬀect of TNF-a on cyclin D1 content. In fact,
the observed eﬀect of the cytokine on the TAM67-expressing
cells was completely opposite: TNF-a treatment actually re-
sulted in a decreased cyclin D1 content when the AP-1 signal-
ing cascade was blocked (Fig. 5).
In summary, the data presented here clearly support a role
for the AP-1 signaling cascade in muscle wasting associated
with cancer. In addition, it may be suggested that, at least
for TNF-a, AP-1 also seems to be involved in the course of
events. However, more studies are necessary to ﬁnd out if
AP-1 is also involved in the intracellular signaling of other pro-
posed muscle wasting mediators such as IL-6 or tumour fac-
tors, such as PIF. These studies are particularly important
since they may lead to the possibility of introducing drugs able
to block the referred signaling cascade which may, in future,
constitute a promising therapeutic strategy for the successful
treatment of cancer cachexia and muscle wasting associated
with other catabolic states.Fig. 5. Cyclin D1 content in control and tumour-bearing rats treated
with AdCMV-TAM67. For full details, see Section 2. The results are
means ± S.E.M. of a minimum of 4 animals for group. Non-infected
(N.I.), AdCMV-TAM67 (TAM67), AdCMV-GFP (GFP). Statistical
analysis of the results (Student’s t test): control vs. TNF-a \, P 6 0.05;
AdCMV-GFP vs. AdCMV-TAM67 , P 6 0.05.
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